The C3i Program is based on the Coulter Commercialization Process, an approach to biomedical research translation, developed and continuously refined by the Wallace H. Coulter Foundation in collaboration with its academic partners across the country. Since 2001, the Foundation has supported more than 400 interdisciplinary teams of scientists and engineers, to bring the latest biomedical innovations to market for the benefit of human health and society at-large. To-date, 77 projects have raised $3 billion in venture capital, 46 projects have been licensed to industry partners, and dozens more have received SBIR support. Most importantly, these efforts have given risen to more than 22 products, with 20 more advancing through Phase II or III clinical trials. The key features and elements which define the Coulter Commercialization Process have been captured and condensed into an intensive, fast-paced boot camp, the C3i Program.